What is the most likely diagnosis and first‑line therapy for a red, scaly rash localized to the nasolabial folds that worsens with heat and sweating?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 25, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Seborrheic Dermatitis: Diagnosis and First-Line Treatment

The most likely diagnosis is seborrheic dermatitis, and first-line therapy consists of ketoconazole 2% cream applied once daily to the nasolabial folds for 2-4 weeks, combined with avoidance of heat triggers and alcohol-containing products. 1, 2, 3

Clinical Diagnosis

Seborrheic dermatitis presents as symmetric, well-demarcated, dull or yellowish-red patches with overlying adherent, greasy (not dry) yellowish scales in the nasolabial folds—a classic distribution for this condition. 4, 5 The worsening with heat and sweating is characteristic, as hypohidrosis from hyperkeratotic plugging of sweat ducts and thermodysregulation are recognized features. 6

The nasolabial fold location is pathognomonic, as seborrheic dermatitis characteristically affects areas rich in sebaceous glands including the nasolabial folds, glabella, eyebrows, and scalp. 7, 4, 8

First-Line Treatment Algorithm

Primary Antifungal Therapy

  • Apply ketoconazole 2% cream once daily to affected nasolabial areas for 2-4 weeks until clinical clearing. 1, 2, 3 This addresses the underlying Malassezia yeast overgrowth that drives the greasy scaling and inflammation. 1, 9

Adjunctive Anti-Inflammatory Therapy

  • For significant erythema and inflammation, add hydrocortisone 1% cream once or twice daily for short periods only (maximum 1-2 weeks). 1, 2 This is critical: only low-potency steroids should ever be used on facial skin, as medium- or high-potency agents (triamcinolone, mometasone, clobetasol) cause unacceptable skin atrophy and telangiectasia. 1

Essential Supportive Measures

  • Avoid all alcohol-containing preparations on the face—these markedly worsen dryness and trigger flares. 1, 2
  • Use tepid (not hot) water for cleansing, as hot water exacerbates symptoms. 1
  • Apply fragrance-free moisturizers containing urea 10% or glycerin to damp skin after cleansing to restore barrier function. 1
  • Avoid harsh soaps—use mild, pH-neutral (pH 5) non-soap cleansers or dispersible creams as soap substitutes to preserve natural skin lipids. 1, 2

Managing Heat and Sweating Triggers

Since this patient's rash worsens with heat and sweating:

  • Recommend avoiding extreme temperatures and outdoor activities during hot periods. 6
  • Suggest regular cooling measures including cold water sprays, fans, and air conditioning to manage thermodysregulation. 6
  • Continue regular topical skincare as this may help reduce hyperkeratotic plugging of sweat glands. 6

Maintenance and Relapse Prevention

  • After initial clearing, continue ketoconazole 2% cream once weekly as prophylactic maintenance to prevent relapse, which significantly reduces recurrence rates. 2
  • Continue daily emollient use even when the condition appears controlled. 1

When to Refer to Dermatology

Refer if: 1, 4

  • No clinical improvement after 4 weeks of appropriate first-line therapy
  • Diagnostic uncertainty or atypical presentation
  • Increased crusting, weeping, or pustules suggesting bacterial superinfection (treat with oral flucloxacillin if Staphylococcus aureus is suspected) 1
  • Grouped vesicles or punched-out erosions suggesting herpes simplex superinfection (requires immediate oral acyclovir) 1

Critical Pitfalls to Avoid

  • Never use medium- or high-potency topical corticosteroids on the face—the risk of atrophy, telangiectasia, and tachyphylaxis is unacceptably high. 1
  • Do not use corticosteroids continuously beyond 2-4 weeks on facial skin, even low-potency agents. 1, 2
  • Avoid greasy or occlusive products that can promote folliculitis. 1
  • Do not confuse persistent mild itching after treatment with treatment failure—mild burning or itching from inflammation can persist for days after yeast elimination. 1

References

Guideline

Treatment Options for Seborrheic Dermatitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Seborrheic Dermatitis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Seborrheic dermatitis: an overview.

American family physician, 2006

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Seborrheic Dermatitis in Skin of Color: Clinical Considerations.

Journal of drugs in dermatology : JDD, 2019

Research

Seborrheic Dermatitis: Diagnosis and Treatment.

American family physician, 2025

Research

Treatment of seborrheic dermatitis.

American family physician, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.